Choose COSENTYX® (secukinumab) at the start, with flexibility along the way
Start early at the first sign of moderate hidradenitis suppurativa (HS),1-3 with dosing options for adult and pediatric patients ≥12 years with moderate to severe HS1
COSENTYX offers flexibility that you can tailor to your patients’ needs
*After 300 mg once weekly (for 5 weeks) initial dosing.1
†After initial 4.5 mg/kg loading dose at Weeks 0, 2, and 4.1
Flexible maintenance dosing for adult patients1‡
Just one UnoReady® Pen per dose
.
Get your patients started with the UnoReady Pen
Suggested prescribing approach1
1 prescription for
loading dose
(Weeks 0, 1, 2, and 3)
1 prescription for maintenance dose
Covers Week 4 loading dose as well as maintenance dose.
If a patient does not adequately respond, consider increasing the dosage to 300 mg every 2 weeks.
COSENTYX is the first and only IL-17A antagonist to offer BOTH SC and IV dosing options for adult patients with moderate to severe HS1,5
For pediatric patients ≥12 years of age1||
Weight-based dosage is administered by subcutaneous injection at Weeks 0, 1, 2, 3 and 4 and every 4 weeks thereafter.
For patients ≥30 kg and <90 kg, the recommended dose is 150 mg
For patients ≥90 kg, the recommended dose is 300 mg
§With the UnoReady Pen. If using the Sensoready pen, your patient will need 2 pens for each dose.
||Inform patients and caregivers that pediatric patients should not self-administer COSENTYX.
Definitions
ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; IL, interleukin; IV, intravenous; Q2W, every 2 weeks; Q4W, every 4 weeks; SC, subcutaneous.
References
1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.
2. Martorell A, Giovanardi G, Gomez-Palencia P, Sanz-Motiva V. Defining fistular patterns in hidradenitis suppurativa; impact on the management. Dermatol Surg. 2019;45(10):1237-1244.
3. Shih T, De D, Daveluy SD, et al. Real-world considerations of candidacy for biologics in hidradenitis suppurativa. Am J Clin Dermatol. 2022;23(6):749-753.
4. Molina-Leyva A, Cuenca-Barrales C. Adolescent-onset hidradenitis suppurativa: prevalence, risk factors and disease features. Dermatology. 2019;235(1):45-50.
5. Bimzelx. Prescribing information. UCB Inc.